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ABSTRACT 
 
Lactate concentrations in the blood or serum are currently used as prognostic 
indicators of certain diseases in human and veterinary medicine. Lactate concentrations 
in the feces are of interest because it is a metabolic product of fermentation by the 
intestinal microbiota. However, no cost effective method to quantify the D- and L-
isoforms of lactate in canine feces is currently available. Therefore, the main objectives 
of this study were to modify and validate an enzymatic assay for the quantification of D-
, L-, and total lactate in canine feces, and to characterize fecal lactate concentrations and 
bacterial abundances in healthy dogs and dogs with gastrointestinal diseases.  
The enzymatic assay was validated with surplus homogenized fecal samples by 
determination of dilutional parallelism, spiking recovery, and intra- and inter-assay 
variability. Fecal samples were collected from healthy dogs (n=34), dogs with acute 
hemorrhagic diarrhea (AHD; n=20), dogs with chronic enteropathy (CE; n=15), and 
dogs with exocrine pancreatic insufficiency (EPI; n=34). Fecal lactate was measured 
with the new enzymatic assay and 11 bacterial groups were quantified with qPCR.  
A canine fecal lactate reference interval was established from 34 healthy dogs 
and was 0.7-1.4 mM, 0.3-6.0 mM, and 1.0-7.0 mM for D-, L-, and total lactate, 
respectively. The assay for measurement of D-, L-, and total lactate in canine fecal 
samples was linear, accurate, precise, and reproducible. Significant increases in fecal 
lactate concentrations were observed in dogs with acute hemorrhagic diarrhea, dogs with 
chronic enteropathy (D-lactate only), and dogs with exocrine pancreatic insufficiency. 
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Blautia spp. and Clostridium hiranonis abundances were decreased in all diseased 
groups of dogs compared to healthy dogs. Dogs with EPI that were receiving enzyme 
replacement therapy had an increased abundance of Lactobacillus spp. and 
Bifidobacterium spp., and all dogs with EPI had an increased Dysbiosis Index compared 
to healthy dogs.  
In conclusion, further studies are necessary to determine the clinical utility of 
lactate quantification in canine feces. Though lactate by itself may not be a good 
indicator of dysbiosis, bacterial metabolites together with bacterial abundances are 
promising targets for further elucidating the role of the microbiota in health and disease.  
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NOMENCLATURE 
 
AHD   acute hemorrhagic diarrhea 
ATP   adenosine triphosphate 
CE   chronic enteropathy 
cTLI   canine trypsin-like immunoreactivity 
EPI   exocrine pancreatic insufficiency 
GC-MS  gas chromatography coupled to mass spectrometry 
GI   gastrointestinal 
GSH   glutathione 
HPLC   high-pressure liquid chromatography 
IBD   inflammatory bowel disease 
LAB   lactic acid bacteria 
LDH lactate dehydrogenase 
LLOD lower limit of detection 
LLOQ lower limit of quantification 
MCT monocarboxylic acid transporter 
MG methylglyoxal 
MM master mix 
NAD nicotinamide adenine dinucleotide 
NADH reduced form of NAD 
OE% observed-to-expected ratio 
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qPCR quantitative polymerase chain reaction 
SBS short bowel syndrome 
SCFAs short chain fatty acids 
SMCT Na+-coupled monocarboxylic acid transporters 
%CV coefficient of variation 
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1. INTRODUCTION  
 
1.1 Lactate Production, Absorption, Clearance 
Lactate is present in the body in two isoforms: D- and L-lactate. L-lactate is 
produced from pyruvate via lactate dehydrogenase (LDH) primarily during anaerobic 
glycolysis or intense exercise, when cell respiration alone cannot keep up with demands 
for nicotinamide adenine dinucleotide (NAD). Glycolysis is the first step in glucose 
metabolism and produces pyruvate, which, under aerobic conditions, is then transferred 
into the mitochondria. Here pyruvate undergoes oxidative decarboxylation and enters the 
Krebs Cycle producing approximately 30 molecules of adenosine triphosphate (ATP) 
per molecule of glucose (Berg et al., 2002). However, in anaerobic conditions, pyruvate 
cannot undergo oxidative decarboxylation and, therefore, needs to be converted to 
lactate in order to continue production of ATP. Production of lactate generates NAD, 
which is then recycled for use in more glycolysis reactions ending with a net production 
of only two ATP molecules per molecule of glucose (Figure 1). Some cells that lack 
mitochondria, such as erythrocytes, use anaerobic glycolysis as their main source of 
energy (De Backer, 2003). Although all cells will produce L-lactate, the majority of 
production in humans is attributable to skeletal muscle, erythrocytes, brain cells, and the 
renal medulla (Fall and Szerlip, 2005).  
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Figure 1. D- and L-lactate formation in the cell. Pyruvate is formed from glycolysis 
reactions and subsequently converted to L-lactate under anaerobic conditions. 
Methylglyoxal (MG) is formed by fragmentation of intermediates in the glycolysis 
pathway, and glutathione (GSH) is formed in conjunction with intermediates entering 
the pentose phosphate pathway (Allaman et al., 2015). GSH works with glyoxalase I and 
II enzymes to detoxify MG into D-lactate.  
 
D-lactate is produced in even smaller amounts by the host via methylglyoxal 
(MG) metabolism (Figure 1). MG is present in all cells and is a by-product of glucose, 
protein, and fatty-acid metabolism (Allaman et al., 2015). It is highly reactive with 
nucleic acids and proteins and, therefore, needs to be degraded to protect cell integrity 
(Thornalley, 1996). MG is also a potent glycating agent that can react with protein 
residues to form advanced glycation end products (Bélanger et al., 2011). The glyoxalase 
 3 
 
system uses the enzymes glyoxalase I and II to detoxify MG into D-lactate (Thornalley, 
1993).  
The intestinal microbiota is the collection of microorganisms that reside within 
the gastrointestinal (GI) tract and interact with each other and with host cells. Many of 
these microorganisms, specifically bacteria, have fermentative capabilities that allow 
them to produce organic acids that are then absorbed and utilized by the host. Bacterial 
groups cumulatively referred to as lactic acid bacteria (LAB) also produce lactate within 
the host GI tract. LAB are defined as bacteria that form lactate as a predominant product 
of carbohydrate fermentation (Liu, 2003). The lactate isomer produced depends on the 
genus, species, and sometimes the strain of bacteria (Table 1). The genus 
Bifidobacterium also produce lactate but are not considered LAB because they produce 
lactate and acetate in a 2:3 ratio (Stiles and Holzapfel, 1997).  
Another source of D- and L-lactate in the GI tract is from dietary intake of 
fermented foods, such as yogurt and sauerkraut (Uribarri et al., 1998). Lactate-producing 
bacteria are often used in these foods as well as probiotics because they can have 
beneficial properties in the gut, such as lowering luminal pH and acting against 
pathogenic bacteria (Gilliland, 1990; Swanson et al., 2002a). Nutritional studies often 
aim to increase lactate concentrations or LAB abundance within the GI tract by 
supplementing fiber in the diet. Fructooligosaccharide supplementation in dogs produced 
minor increases in fecal lactate and LAB populations and improved some indicators of 
intestinal immune function (Swanson et al., 2002a; Swanson et al., 2002b). However, 
results from human studies contradicted these findings, showing that resistant starch  
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Table 1. Lactate isomers produced by bacteria in the gastrointestinal tract. 
D-lactate Both L-lactate Reference 
Leuconostoc, 
Oenococcus 
Lactobacillus, 
Pediococcus, 
Weissella 
Aerococcus, 
Carnobacterium, 
Enterococcus, 
Lactococcus, 
Tetragenococcus, 
Streptococcus, 
Vagococcus 
Liu, 2003 
Leuconostoc Lactobacillus, 
Pediococcus (except 
L.dextrinicus) 
Bifidobacterium, 
Lactococcus, 
Enterococcus 
Stiles and 
Holzapfel, 
1997 
  Enterococcus faecalis 
(primarily D-lactate), 
Streptococcus 
sanguinis (primarily 
D-lactate), 
Escherichia coli 
(primarily L-lactate) 
  Sheedy et 
al., 2009 
 
 
supplementation and LAB probiotics failed to increase fecal lactate concentrations 
(Phillips et al., 1995; Matsumoto and Benno, 2004). Lowering of intestinal pH may have 
a larger role in the effectiveness of these dietary supplements, but Phillips et al. (1995) 
suggested that increased production of short chain fatty acids (SCFAs) and not lactate 
was responsible for this acidification. Furthermore, Edwards et al. (1985) found that 
changes in pH modified metabolic activities of bacteria without changing the bacterial 
population. Studies by Jiang and Savaiano (1997) showed that, in an acidic environment 
(pH 6.2), more SCFAs were produced, and there was a significant reduction in the 
amount of D-lactate. It was long thought that humans do not readily metabolize D-
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lactate, which led to the World Health Organization recommending a limited intake of 
the D-lactate isomer (Jehanno et al., 1992). Consequently, attempts have been made to 
decrease the proportion of D-lactate producing organisms in fermented foods and L-
lactate producers have become favorable (Liu, 2003). However, experiments by de 
Vrese et al. (1990) showed that long-term ingestion of D-lactate did not produce an 
accumulation of lactate in the body.  
 Under normal conditions, the intestinal microbiota has the capacity to further 
metabolize D- and L-lactate into other SCFAs that can be beneficial to the host 
(Halperin and Kamel, 1996). Human fecal microbiota cultures have been shown to 
convert D- and L-lactate to butyrate, acetate and propionate (Duncan et al., 2004; 
Bourriaud et al., 2005; Morrison et al., 2006; Belenguer et al., 2007). Specific bacterial 
groups implicated in these processes include Veillonella parvula and Propionibacterium 
freudenreichii (Seeliger et al., 2002), which convert lactate to acetate and propionate, 
and Megasphaera elsdenii (Counotte et al., 1981; Hashizume et al., 2003), which 
converts lactate to butyrate. More recently, Duncan et al. (2004) identified strains of 
Eubacterium hallii and Anaerostipes caccae as well as a new species within the 
Clostridium cluster XIVa that utilize lactate to form butyrate as an end product. 
Although the intestinal microbiota can lower lactate concentrations in the GI tract by 
utilizing it, they generally do not metabolize all of it. Healthy humans have a fecal 
lactate concentration of less than 3 mmol/L (Duncan et al., 2007), indicating that any 
lactate unused by bacteria is either absorbed by the host, or excreted in the feces.  
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Multiple studies in cows (Preston and Noller, 1974; Wolffram et al., 1988), sheep 
(Ding and Xu, 2003), and rats (Ogihara et al., 2000) have shown that lactate is absorbed 
through the intestinal epithelium. There are three mechanisms for lactate absorption or 
transport across cell membranes: carrier-mediated transport by monocarboxylic acid 
transporter (MCT), exchange with inorganic anions, and passive diffusion (Poole and 
Halestrap, 1993; Ding and Xu, 2003; Allen and Holm, 2008). Absorption is somewhat 
concentration-dependent suggesting the presence of saturable and nonsaturable 
mechanisms (Ogihara et al., 2000). Tamai et al. (1995) demonstrated the presence of H+-
coupled monocarboxylate transporter MCT1 in rat intestinal epithelial cells and that the 
transporter had a higher affinity for L-lactate with an uptake coefficient twice that of D-
lactate. D- and L-lactate uptake by MCT1 is inhibited by acetate, propionate, butyrate, 
benzoic acid, nicotinic acid, pravastatin, and valproic acid (Wolffram et al., 1988; Tamai 
et al., 1995). Furthermore, monocarboxylic acid uptake by MCT1 increases in acidic pH, 
and uptake of L-lactate is stereoselectively inhibited by ibuprofen, a monocarboxylic 
drug (Tamai et al., 1995; Tachikawa et al., 2011).  
A second class of MCTs that contribute to the absorption of lactate from the 
intestine are Na+-coupled monocarboxylic acid transporters (SMCT). SMCT1 (SLC5A8) 
is present on the luminal surface of intestinal epithelial cells and facilitates absorption of 
SCFAs and lactate (Poole and Halestrap, 1993; Ganapathy et al., 2008). Similar to the 
H+-coupled MCT1, SMCT1 exhibits a higher affinity for L-lactate compared to D-lactate 
(Miyauchi et al., 2004; Martin et al., 2006). Ibuprofen and other non-steroidal anti-
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inflammatory drugs also block uptake of other substrates by SMCT1 (Ganapathy et al., 
2008).  
Lactate produced by host cells through anaerobic glycolysis and methylglyoxal 
metabolism, and lactate absorbed from the intestine, ends up in the blood. Several 
physiological mechanisms are present in the host that regulate the amount of lactate in 
the blood to prevent accumulation and disturbance of acid-base homeostasis. The liver 
and kidneys are the main organs responsible for clearing lactate from the blood and are 
able to clear 50-70% and 20-30%, respectively, of blood lactate (Yudkin and Cohen, 
1975; Madias, 1986; Pang and Boysen, 2007; Allen and Holm, 2008; Vernon and 
LeTourneau, 2010). One of the ways these organs clear lactate is by metabolizing it to 
pyruvate and glucose. The enzymes implicated in this process are L-lactate 
dehydrogenase, D-lactate dehydrogenase, and d-2-hydroxyacid-dehydrogenase, all of 
which have been isolated from mammalian liver and kidney (Tubbs, 1965; Cammack, 
1969; de Bari et al., 2002; Flick and Konieczny, 2002; Ewaschuk et al., 2005).  
L-lactate dehydrogenase, like L-lactate, is more abundant than D-lactate 
dehydrogenase, and it is widespread in multiple tissue types, including skeletal muscle 
(Flick and Konieczny, 2002). It was historically thought that mammals lacked the ability 
to efficiently metabolize D-lactate. Then studies in the 1960s described d-2-
hydroxyacid-dehydrogenase in the liver and kidney of mammals that metabolizes D-
lactate to pyruvate, albeit at a much slower rate than L-lactate dehydrogenase 
metabolizes L-lactate (Tubbs, 1965; Cammack, 1969). Experiments by de Vrese et al. 
(1990) confirmed presence and activity of d-2-hydroxyacid-dehydrogenase in humans. 
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In the early 2000s, D-lactate dehydrogenase was isolated in rodents and humans (de Bari 
et al., 2002; Flick and Konieczny, 2002). It is localized mainly within mitochondria of 
the liver and kidney but is also present in mitochondria of other tissues as well (de Bari 
et al., 2002; Flick and Konieczny, 2002). Using rat liver mitochondria, de Bari et al. 
(2002) identified three translocators that move D-lactate across the mitochondrial 
membrane: the D-lactate/H+ symporter, and the D-lactate/oxoacid or malate antiporters. 
Once D-lactate is in the mitochondria, it is oxidized into pyruvate, which can then either 
enter the Krebs cycle to produce ATP or be converted into glucose via gluconeogenesis. 
Different types of tissue oxidize D- and L-lactate at different rates. Studies of bovine 
tissues revealed that rates of D- and L-lactate oxidation were greatest in the kidney, 
followed by heart, liver, and muscle tissue (Harmon et al., 1984). Brandt et al. (1984) 
used radiolabeled lactate in rat tissues and found that brain and kidney tissue oxidized L-
lactate more efficiently than D-lactate, whereas the opposite was true in liver tissue.  
Na+-coupled MCTs are also present in the kidney epithelia, where they actively 
reabsorb lactate (Ganapathy et al., 2008). L-lactate is reabsorbed in the proximal 
convoluted tubule more readily than D-lactate and the isomers exhibit mutual 
interference (Oh et al., 1985; Halperin and Kamel, 1996). Passive diffusion along a 
lactate concentration gradient created by removal of lactate by oxidation within the 
kidney cells might contribute to reabsorption (Hohmann et al., 1974).  
Aside from metabolism of lactate by oxidation, the kidneys also contribute to 
lactate clearance through excretion in the urine. Estimates of lactate elimination through 
renal excretion vary from less than 2% to almost 20% with excretion of D-lactate being 
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greater than excretion of L-lactate (Connor et al., 1983; Oh et al., 1985; de Vrese et al., 
1990). However, renal excretion increases with increased blood lactate concentration 
and in metabolic acidosis (Harmon et al., 1984; Allen and Holm, 2008), which could be 
the reason behind some of the variation noted above. Some of the variation may be 
attributable to species differences as well. Giesecke et al. (1981) suggested that rats and 
rabbits may differ in their renal threshold values for excretion of D-lactate, and Oh et al. 
(2010) compared his data in humans to that of dogs and suggested that humans do not 
reabsorb D-lactate in the kidneys as efficiently as dogs.  
 
1.2 Blood Lactate Concentrations 
Normal lactate concentration in whole blood of healthy humans is less than 2 
mmol/L with the L- isomer comprising about 98% (Huckabee, 1961; Allen and Holm, 
2008; Vernon and LeTourneau, 2010). D-lactate is present in plasma of healthy adults 
only in small amounts ranging from 0.01 to 0.07 mmol/L (Brandt et al., 1980; de Vrese 
and Barth, 1991; McLellan et al., 1992). This is possibly due to the kidney preferentially 
excreting D-lactate and preferentially reabsorbing L-lactate (Oh et al., 1985). Similar to 
humans, plasma lactate concentrations of dogs and cats are generally less than 2 mmol/L 
(Pang and Boysen, 2007). In healthy adult dogs, plasma lactate ranges from 0.3 to 3.6 
mmol/L, but there is a slightly higher range in puppies indicating the need to be cautious 
when interpreting values from younger animals (Evans, 1987; Hughes et al., 1999; 
McMichael et al., 2005). Hughes et al. (1999) also found that small differences in 
plasma lactate concentrations can be caused by different sample collection sites and 
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repeated sampling. Any differences due to these variables can be avoided by using the 
same procedure in a clinical setting as was used to obtain the reference interval. Though 
small, these differences should be kept in mind when comparing data between studies 
that used different sample collection or handling techniques. Rand et al. (2002) also 
found that struggling in cats can increase plasma lactate concentrations by up to ten-fold. 
This should be considered when interpreting clinical data against the resting reference 
interval. 
When there is a malfunction of one or more of the systems involved in lactate 
production or clearance, a condition called lactic acidosis can occur. Lactic acidosis is 
defined as having a blood lactate concentration ≥ 5 mmol/L associated with a decrease in 
blood pH, whereas hyperlactatemia occurs without change in blood pH and an increase 
to only 2 to 5 mmol/L blood lactate (Mizock and Falk, 1992). Uribarri et al. (1998) 
defined D-lactic acidosis specifically as having metabolic acidosis accompanied by ≥ 3 
mmol/L serum D-lactate. L-lactic acidosis is typically caused by tissue hypoxia or 
underlying diseases, such as sepsis, liver disease, diabetes mellitus, or respiratory failure 
(Ewaschuk et al., 2005; Sharkey and Wellman, 2015). L-lactic acidosis is more common 
in humans and animals than D-lactic acidosis, and therefore this isoform is more often 
measured than D-lactate in the clinical setting (Ewaschuk et al., 2005; Sharkey and 
Wellman, 2015).  
In cases of D-lactic acidosis, the excess lactate originates from bacterial 
production of this isoform in the intestinal lumen. Unlike L-lactic acidosis, D-lactic 
acidosis is characterized by episodes of encephalopathy that are often worsened in 
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conjunction with food intake (Uribarri et al., 1998; Ewaschuk et al., 2005). Furthermore, 
D-lactic acidosis has been reported in diseases associated with alterations in the 
intestinal microbiota, such as short bowel syndrome (SBS) in humans (Kowlgi and 
Chhabra, 2015), diarrhea in calves (Lorenz, 2004), and exocrine pancreatic insufficiency 
(EPI) in a cat (Packer et al., 2005). D-lactic acidosis has also been tentatively associated 
with antibiotic (Coronado et al., 1995) and probiotic use (Munakata et al., 2010) in 
human patients with SBS. However, these were single case reports and more 
comprehensive studies are needed to examine the association between antibiotic and 
probiotic use and acidosis. Serial measurements of whole blood or plasma lactate 
concentrations in critically ill dogs are used to predict patient outcome, determine the 
severity of disease, and assess treatment response (Nel et al., 2004; Mooney et al., 2014; 
Cortellini et al., 2015; Sharkey and Wellman, 2015; Eichenberger et al., 2016). Though 
plasma or blood lactate concentration is useful in a clinical setting, we can gain a better 
understanding of the role of lactate in the GI tract by measuring it closer to the source, in 
the feces. 
 
1.3 Microbiota and Lactate in Health and Disease 
There is mounting evidence of the relationship between the intestinal microbiota, 
the metabolites it produces (such as lactate), and health and disease (Blake and 
Suchodolski, 2016). In humans, it has been implicated that certain metabolites produced 
by the intestinal microbiota may influence host metabolism (Morrison and Preston, 
2016). Methods to characterize the intestinal microbiota have evolved from traditional 
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bacterial culture methods to high-throughput sequencing of the entire metagenome. 
However, quantitative polymerase chain reaction (qPCR) is often employed to measure 
abundance of specific bacterial groups. An extensive review of the role of the intestinal 
microbiota in dogs and cats is available elsewhere (Blake and Suchodolski, 2016). 
With lactate being a major metabolite of bacterial origin, examining the lactate 
concentrations in the feces should provide us with an idea of disturbances to the GI 
microbiota. Lactate does not usually accumulate in the GI tract in a healthy state, as 
denoted by a fecal lactate concentration in healthy humans of 0 to 3 mmol/L (Duncan et 
al., 2007). However, in a disease state, fecal lactate can become increased (Bustos et al., 
1994; Sato and Koiwa, 2008; Mayeur et al., 2013). There are several theories why 
lactate accumulates in the GI tract. Ewaschuk et al. (2005) describes the process in SBS 
as a series of events: poor carbohydrate digestion results in sugars being delivered to the 
colon, where the pH is decreased by organic acid production through fermentation, 
finally resulting in acid-resistant Lactobacillus spp. growing preferentially. In vitro 
studies by Belenguer et al. (2007) point to a different reason for lactate accumulation; 
their work suggests that once the intraluminal pH decreases past a certain point, lactate 
production will be maintained but lactate utilization will decrease. Regardless of why the 
accumulation occurs, it is of interest to determine the metabolic and ecological 
consequences of excess lactate in the intestinal lumen. This is important to gain a better 
understanding of the role that the microbiota plays in the various disease processes 
involving lactate accumulation.  
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As mentioned previously, increased serum lactate is associated with D-lactic 
acidosis in maldigestive disease processes such as SBS in humans (Kowlgi and Chhabra, 
2015), diarrhea in calves (Lorenz, 2004), and EPI in a cat (Packer et al., 2005). 
Interestingly, in human patients with SBS, fecal D-lactate concentrations are increased 
even when serum lactate concentrations are normal (Bustos et al., 1994). Another study 
by Hove and Mortensen (1995) showed that when large amounts of lactulose were fed to 
healthy individuals, fecal D-lactate increased to 13.6 mmol/ L while plasma and urine 
lactate concentrations remained the same. Together, these studies suggest that other 
mechanisms are involved in the development of acidosis, such as increased absorption or 
impaired metabolism of D-lactate. As the focus lies more on changes within the GI tract 
during disease, our focus should then be on lactate concentrations in the feces.  
To obtain a more comprehensive understanding of the role of lactate in GI 
disease, it may be useful to examine fecal lactate concentrations in a variety of diseases 
that have different characteristics. Profound alterations to the intestinal microbiome have 
been identified in dogs with acute hemorrhagic diarrhea (AHD), including decreased 
Lactobacillus, Faecalibacterium, Turicibacter, and Streptococcus, and increased 
Escherichia coli and Clostridium perfringens (Markel et al., 2012; Suchodolski et al., 
2012). Unterer et al. (2014) endoscopically visualized mucosal lesions in the intestines 
of dogs with AHD and isolated C. perfringens on the small intestinal mucosa of two 
thirds of cases. Dogs with chronic enteropathies (CE), such as inflammatory bowel 
disease, also had alterations to their intestinal microbiome, including decreases in 
Faecalibacterium spp. and Fusobacteria, during times of clinically active disease 
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(Suchodolski et al., 2012). Preliminary studies using untargeted fecal metabolomics 
showed an abundance of fecal lactate in dogs with CE (Honneffer et al., 2015). 
However, further studies are warranted to determine the clinical utility of fecal lactate 
concentrations as a marker of dysbiosis. Exocrine pancreatic insufficiency (EPI), much 
like other diseases characterized by maldigestion (i.e., SBS), causes changes to the 
intestinal microbiota. Simpson et al. (1990) reported increased Lactobacillus and 
Streptococcus in the duodenum of dogs with EPI before dogs underwent treatment with 
pancreatic enzyme replacement. Similarly, Westermarck et al. (1993) reported increased 
total counts of bacteria in the small intestine of dogs with EPI, regardless of whether 
they had received therapy. The authors also noted that oral administration of the 
antibiotic tylosin decreased these counts to normal levels.  
 
1.4 Measuring Lactate Concentrations 
Many of the methods used to measure lactate involve enzymes and are dependent 
upon the following reaction (Rosenberg and Rush, 1966): 
Lactate + NAD+  
   LDH   
↔     Pyruvate + NADH + H+ 
The production of NADH, or the reduced form of NAD, can be measured by 
spectrophotometry at 340nm wavelength (Olson, 1962). However, the reaction favors 
production of lactate. Therefore, a pyruvate trapping reaction will allow it to proceed in 
the forward direction and the amount of NADH formed will be directly proportional to 
the amount of lactate in the original sample (Goodall and Byers, 1978). When measuring 
lactate enzymatically in biological samples, it is necessary to deproteinize the samples 
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first to remove potential competitors for NAD+, other enzymes present in the sample, 
and stabilize the lactate molecules (Goodall and Byers, 1978). Both isomers of lactate 
can be measured by utilizing stereospecific forms of LDH, D-LDH and L-LDH (Brandt 
et al., 1980).  
Because L-lactate was shown to be useful clinically early on, methods to measure 
it in a clinical setting evolved. Allen et al. (2008) summarizes the clinical utility of 
lactate in veterinary patients, usually utilized as a prognostic indicator in varying 
diseases from colic to gastric dilatation volvulus. Most hand-held blood lactate analyzers 
used today are based on enzymatic amperometry and measure L-lactate only (Pang and 
Boysen, 2007). The principle behind amperometry is this: lactate oxidase coats an 
electrode and reacts with lactate generating hydrogen peroxide, which then generates an 
electrical current that is proportional to the amount of lactate in the sample (Pang and 
Boysen, 2007; Allen and Holm, 2008). This method is convenient for use in the clinical 
setting and can generate results within minutes (Allen and Holm, 2008). However, many 
of the hand-held lactate analyzers are ill suited to modification for use in other biological 
samples due to their optimization for use with whole blood. For instance, the Lactate 
Scout Plus by EKF Diagnostics makes automatic compensations for hematocrit and 
measures lactate concentrations from 0.5-25 mmol/L (Lactate Scout+, SensLab GmbH, 
Leipzig, Germany). 
Another way of measuring lactate concentrations involves the use of 
chromatography, such as gas chromatography coupled to mass spectrometry (GC-MS) or 
high-pressure liquid chromatography (HPLC). Both of these methods require the use of 
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expensive laboratory equipment that is often available only to reference laboratories. 
GC-MS techniques generally cannot differentiate between D- and L-lactate isomers, 
unless they are multidimensional or coupled to dual mass spectrometers (Heil et al., 
1998). HPLC can be used for stereospecific measurements of lactate (Omole et al., 
1999), but it is more expensive and has a longer turnaround time than GC-MS. Both GC-
MS and HPLC methods have been used to measure lactate in biological samples such as 
urine and serum (Hoffmann et al., 1989; Heil et al., 1998; Omole et al., 1999; Allen and 
Holm, 2008; Packer et al., 2012). However, their limited use with feces is somewhat due 
to the inherent molecular contamination within feces that requires more steps in sample 
preparation and can damage the column.  
Enzymatic spectrophotometry assays are best suited for use with measuring 
lactate in feces. Many studies have utilized these methods previously in human feces 
(Bustos et al., 1994; Mayeur et al., 2013), cow feces (Shimomura and Sato, 2006; Sato 
and Koiwa, 2008), and murine feces (Rul et al., 2011). Swanson et al. (2002a) measured 
lactate concentrations in canine feces using the spectrophotometric method described by 
Barker and Summerson (1941). However, this method is not able to distinguish D- and 
L-lactate. 
 
1.5 Hypothesis and Specific Objectives 
Based on the information presented in the literature, our hypothesis is that fecal 
lactate concentrations are increased in dogs with GI disease. Therefore, the aims of the 
present study were: 1) to modify and validate an enzymatic assay for the quantification 
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of fecal D-, L-, and total lactate in canine feces; 2) to characterize fecal lactate 
concentrations in healthy dogs and dogs with various gastrointestinal diseases; and 3) to 
quantify abundance of lactic acid bacteria in feces by qPCR and to compare to fecal 
lactate concentrations and dysbiosis in dogs with GI disease.  
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2. MATERIALS AND METHODS 
 
2.1 Samples 
Healthy control dogs (n=34) had no signs of GI disease. Fecal lactate 
concentrations from all dogs were used to calculate the healthy reference interval. 
However, due to limited amount of feces, bacterial abundances were quantified in 18 
dogs. These dogs (n=18) were used as the control group for comparisons of lactate and 
bacterial abundances between healthy and diseased dogs.  
Dogs with acute hemorrhagic diarrhea (AHD; n=20) underwent diagnostic 
workup to exclude other causes of disease. Acute was defined as duration of diarrhea 
less than three days. Feces were collected before any treatment was started. 
Dogs with chronic enteropathy (CE; n=15) had GI signs for more than 3 weeks 
and had histopathologic findings consistent with CE. Feces were collected prior to 
endoscopy and bowel cleanse.  
Dogs with exocrine pancreatic insufficiency (EPI; n=34) were diagnosed by a 
serum trypsin-like immunoreactivity (cTLI) of less than 2.5 µg/L. Dogs were separated 
into two groups; those that were currently receiving pancreatic enzyme replacement 
therapy (treated EPI, n=29) and those that had not yet received therapy (untreated EPI, 
n=5). Duration of enzyme replacement therapy was obtained for a subset of the dogs 
treated for EPI (n=12). 
All dogs included in our analysis were client owned, and all feces collected were 
naturally voided and so Institutional Animal Care and Use Committee approval was not 
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needed. Dogs were at least one year of age and had not received antibiotics for at least 
three weeks prior to sample collection. All fecal samples were received frozen or cool on 
dry ice or ice packs. Once received at the laboratory, the feces were either immediately 
aliquoted then stored at -80°C (treated EPI samples; n=12), or stored at -80°C for 
aliquoting at a later date (all other samples). Please refer to Table 2 below for collection 
information and shipping conditions on the various samples.  
 
Table 2. Fecal sample collection details. 
Group and Number Collection 
Storage and Shipping 
Conditions 
healthy (n=34) single TP (n=16), 3 
consecutive bowel 
movements, pooled (n=18) 
-80°C, ice packs 
overnight shipping 
AHD (n=20) single TP -80°C, dry ice 
CE (n=15) single TP -80°C, dry ice and ice 
packs overnight 
shipping 
treated EPI (n=29) single TP (n=12), 3 
consecutive bowel 
movements, pooled (n=17) 
-80°C, ice packs, 
overnight shipping 
untreated EPI (n=5) 3 consecutive bowel 
movements, pooled 
-80°C, ice packs, 
overnight shipping 
TP = time point, AHD = acute hemorrhagic diarrhea, CE = chronic 
enteropathy, treated EPI = dogs with exocrine pancreatic insufficiency 
receiving enzyme replacement therapy, untreated EPI = dogs with exocrine 
pancreatic insufficiency not receiving enzyme replacement therapy 
 
2.2 Materials 
The following materials were used: 
6N Trichloroacetic acid Sigma-Aldrich, St. Louis, MO, USA 
 20 
 
D-/L-lactate Enzymatic Kit R-Biopharm Inc., Washington, MO, 
USA 
PowerSoil® DNA Isolation Kit MOBIO Laboratories, Inc., Carlsbad, 
CA, USA 
SsoFast™ EvaGreen® Supermix Bio-Rad Laboratories, CA, USA 
Triethanolamine Sigma-Aldrich, St. Louis, MO, USA 
 
2.2.1 Instruments and Machines 
 The following instruments and machines were used: 
AutoRep E pipette Rainin, Woburn, MA, USA 
Centrifuge 5424R Eppendorf AG, Hamburg, Germany 
Centrifuge rotor FA-45-24-11 Eppendorf AG, Hamburg, Germany 
Centrifuge, Galaxy Mini VWR, West Chester, PA, USA 
epBlue v10.09.0000 software Eppendorf AG, Hamburg, Germany 
epMotion 5075 Vacuum TMX Eppendorf AG, Hamburg, Germany 
Gen5 2.07 plate reader software BioTek® Instruments, Inc., 
Winooski, VT, USA 
Lyophilizer - FreeZone 2.5Plus LABCONCO Corporation, Kansas 
City, MO, USA 
Nanodrop 1000 software v3.8.1 Thermo Scientific, Rockford, IL, 
USA 
pH-meter - Orion Star A211 Thermo Scientific, Rockford, IL, 
USA 
Pipetman® P-2, P-20, P-100, P-200, P-
1000 
Rainin, Woburn, MA, USA 
Pipette E4XLS P-20, P-100, P-300, P-
1000 
Rainin, Woburn, MA, USA 
Plate incubator - Stat Fax - 2200 Awareness Technology Inc., Palm 
City, FL, USA 
PURELAB® Ultra Water Purification 
System, ELGA LabWater 
VWR, West Chester, PA, USA 
qPCR thermal cycler - CFX96TM Bio-Rad Laboratories, CA, USA 
Scale - Voyager Pro Ohaus, Parsippany, NJ, USA 
Scale - XS6002S Mettler Toledo, Columbus, OH, 
USA 
Shaker - Micromix 5 DPC Cirrus Inc., Flanders, NJ, USA 
Spectrophotometer, Nanodrop 1000 Thermo Scientific, Rockford, IL, 
USA 
Standard Stirrer VWR, West Chester, PA, USA 
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Statistical software package Prism 5.0 GraphPad software Inc., San Diego, 
CA, USA 
Synergy2 multi-mode plate reader BioTek® Instruments, Inc., 
Winooski, VT, USA 
Vortex mixer Fisher Scientific, Pittsburg, PA, USA 
 
2.2.2 Disposable Materials 
 The following disposable materials were used: 
BioClean™ pipette tips in Green-Pak™ 
(20, 1000 µL) 
Rainin, Woburn, MA, USA 
Blue Max™ Jr., polypropylene tube, 15 
mL 
Falcon, Franklin Lakes, NJ, USA 
Costar® Microcentrifuge tube (1.7 mL) Corning Inc., Corning, NY, USA 
Innoculation loops w/ needle, sterile, 
10 µL, Globe Scientific 
Fisher Scientific, Hampton, NH, 
USA 
Magnetic micro-stir bar VWR, West Chester, PA, USA 
Magnetic stir bar VWR, West Chester, PA, USA 
Microcentrifuge tube, seal-rite® (1.5 
mL) 
USA Scientific, Orlando, FL, USA 
Microcentrifuge tube, seal-rite® (2.0 
mL) 
USA Scientific, Orlando, FL, USA 
Microplates, 96-well, PS, F-bottom, 
clear 
Greiner Bio-One GmbH, Germany 
Microseal® B Adhesive Sealer Bio-Rad Laboratories, CA, USA 
Multiplate® PCR Plates™, 96-well, 
clear, unskirted 
Bio-Rad Laboratories, CA, USA 
Parafilm® VWR, West Chester, PA, USA 
Rainin® pipette tips (10, 250, 1000 µL) Rainin, Woburn, MA, USA 
Screw cap Micro tube, 2 mL Sarstedt, Sarstedtstraße, Germany 
Slef-standing centrifugal polypropylene 
tubes, 50 mL 
Corning Inc., Corning, NY, USA 
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2.3 Quantification of Fecal Lactate 
2.3.1 Deproteinization of Feces 
 Frozen samples were thawed at room temperature for aliquoting. An aliquot of 
125 ± 5 mg feces was made for each fecal sample and placed into 1.5 mL 
microcentrifuge tubes. Aliquots were then stored at -80°C until deproteinization. 
Deproteinization of fecal samples was achieved by using the protocol of Rul et al. (2011) 
with modifications. Briefly, 750 µL of 0.1 M triethanolamine buffer (pH 9.15) was 
added to each fecal aliquot. The tubes were vortexed and placed in the refrigerator 
(~4°C) for three hours, vortexing every hour to ensure thorough mixing. The samples 
were then centrifuged at 13,000 x g for 5 minutes at 4°C. Next, 495 µL of the 
supernatant was carefully pipetted off into a new 1.5 mL microcentrifuge tube. These 
supernate aliquots were stored at -80°C overnight to provide ample time for the next 
processing steps. From empirical experience, the extra freeze-thaw cycles favorably 
increased protein pellet size while not affecting lactate concentrations. The next 
morning, samples were thawed at room temperature for 20-40 minutes. Once thawed, 10 
µL of 6 M trichloroacetic acid was added to each sample. The samples were vortexed for 
10 seconds and placed in an ice bath for 20 minutes. Then samples were vortexed for a 
few seconds and centrifuged at 4,500 x g for 20 minutes at 4°C. After centrifugation, a 
protein pellet was noted in the bottom of each tube. Next, 400 µL of supernatant was 
pipetted off into a 2 mL microcentrifuge tube and 1600 µL 0.1 M triethanolamine buffer 
(pH 9.15) added to achieve a neutral or alkaline pH (between 7 and 10). These 
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deproteinized fecal extracts were either used immediately for lactate analysis or stored in 
-80°C for later use.  
 
2.3.2 Spectrophotometric Analysis 
Ultraviolet spectrophotometric analysis of fecal lactate was performed using a 
commercially available enzymatic kit (D-/L-Lactate Enzymatic Kit, R-Biopharm Inc.) 
with modifications to the manufacturer protocol for use with a 96-well plate format. The 
concentrations of D- and L-lactate were determined by measuring the sequential 
formation of NADH by the increase in absorption at 340 nm wavelength following 
addition of stereospecific D- and L-LDH (Supplemental material; manufacturer protocol 
for D-/L-lactic acid kit). The protocol was modified for use with a 96-well plate format 
by dividing all volumes by a factor of ten. Standard dilutions were made for D- and L- 
lactate by the addition of ultra-pure water (PURELAB® Ultra Water Purification 
System, ELGA LabWater; Table 3). Master mix (MM) solution was made on an as 
needed basis depending on the number of samples and consisted of solution 1 (100 µL 
for each sample), 2 (20 µL for each sample), and 3 (2 µL for each sample) mixed in a 15 
or 50 mL tube (Table 4). Blanks, standards, and samples were pipetted in duplicate onto 
a 96-well plate (Table 5) and placed on a plate shaker for one minute. After a 15-minute 
incubation at 25°C, the first absorbance (A1) was read at 340 nm wavelength. Then 2 µL 
D-LDH was added to each well, shook for one minute, and incubated at 25°C for 30 
minutes. The second absorbance (A2) reading was taken and then 2 µL L-LDH added to 
each well, shook and incubated at 25°C for 30 minutes. The third absorbance (A3)  
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Table 3. Standard dilutions of D- and L-lactate. 
Standard Dilution Concentration (g/L) 
1 1:4 0.05175 
2 1:10 0.0207 
3 1:20 0.01035 
4 1:40 0.005175 
5 1:80 0.0025875 
Stock concentration = 0.207 g/L 
  
Table 4. Description of solutions included in enzymatic kit. 
Solution 
Number 
Description* 
1 approx. 30 ml solution, consisting of: 
glycylglycine buffer, pH approx. 10.0; L-
glutamic acid, approx. 440 mg 
2 approx. 210 mg NAD, lyophilizate, 
reconstituted in 6 ml redist. Water 
3 approx. 0.7 ml glutamate-pyruvate 
transaminase suspension, approx. 1100 U 
4 approx. 0.7 ml D-lactate dehydrogenase 
solution, approx. 3800 U 
5 approx. 0.7 ml L-lactate dehydrogenase 
solution, approx. 3800 U 
*Descriptions obtained from manufacturer protocol 
 
Table 5. Samples and reagent volumes. 
Well type Volumes 
blanks 122 µL MM, 100 µL water 
standards (D- and L-lactate) 122 µL MM, 100 µL standards 1-5 
unknown samples 122 µL MM, 100 µL fecal extract 
MM = master mix 
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reading was taken and then data processing was performed. A path length adjustment 
setting was implemented on the plate reader software (Gen5 v. 2.07, BioTek® 
Instruments, Inc.) to account for using a protocol originally designed for use with 1 cm 
diameter cuvettes. Standard curve and lactate concentrations were calculated. The 
standard curve was set to be quadratic and lactate concentrations were adjusted by 
subtracting the absorbance difference of the blank. Then, if D- or L-lactate 
concentrations were below their respective lower limits of quantification (g/L), 
concentrations were adjusted to 0.002 g/L for D-lactate or 0.0007 g/L for L-lactate. Final 
lactate concentrations were also adjusted based on starting weight of the feces, dilution 
factor, and dry matter content (Supplemental material; Excel file with interactive 
formulas and manufacturer protocol for L-lactic acid kit).  
 
2.4 Analytical Validation of the Assay for Measurement of Fecal Lactate 
 Surplus homogenized canine fecal samples from seven dogs were used for 
analytical validation. Validation variables tested were lower limit of detection, lower 
limit of quantification, dilutional parallelism, spiking recovery, and intra- and inter-assay 
variability. Deproteinized fecal extract stability was evaluated by measuring D- and L-
lactate in seven sample extracts at baseline, 24 hours of storage at 4°C, and 28 days of 
storage at -80°C. The reference intervals for canine fecal lactate concentrations were 
calculated from the central 95th percentile from 34 healthy dogs. These dogs were 
determined to be healthy based on evaluations of the owner questionnaires. Dogs had no 
signs of disease and were at least 1 year of age.  
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 Lower limit of detection (LLOD) and lower limit of quantification (LLOQ) were 
assessed by measuring ten duplicates of the blank and calculating the mean and standard 
deviation of the absorbance differences, A2-A1 (D-lactate) and A3-A2 (L-lactate). The 
analytical sensitivity (S) at the lower end of the standard curve was calculated by:  
S =
∆ concentration
∆ intensity
 
where Δ concentration = (concentration standard 4) – (concentration standard 5) = 
0.00259 g/L, and Δ intensity = (ΔA standard 4- ΔA standard 5)-ΔAblank. (ΔA standards 
calculated from average of 8 runs). Next LLOD and LLOQ were calculated by the 
following equations: 
LLOD = ksblS 
LLOQ = ksblS 
where k is chosen based on desired level of confidence (k=3 for LLOD and k=10 for 
LLOQ) and sbl is the standard deviation of the blank.  
 Assay linearity was evaluated by assessing dilutional parallelism for seven 
different fecal samples at dilutions of 1, 1:2, 1:4, 1:10, 1:20, 1:40, and 1:80 for each 
sample. Dilutions were performed by the addition of ultra-pure water (PURELAB® 
Ultra Water Purification System, ELGA LabWater). The accuracy of the assay was 
measured by mixing previously quantified extracts of four samples in a 1:1 ratio. The 
percentage of lactate recovery was calculated as the observed-to-expected ratio (OE%): 
OE% = [
observed value (mM)
expected value (mM)
] × 100 
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To evaluate precision of the assay, four different fecal samples that spanned the working 
range of the assay were analyzed 8 times within the same assay run on one single plate. 
The intra-assay coefficient of variation (%CV) was calculated as: 
%CV = (
standard deviation
mean
) × 100 
The reproducibility of the assay was evaluated by analyzing seven different fecal 
samples in 8 separate assay runs on different days, followed by calculation of inter-assay 
%CVs. All fecal validation samples were run in duplicate and at dilutions that allowed 
them to fall within the working range of the assay.  
 
2.5 Quantification of Bacterial Groups in Feces 
 A 600-1200 mg aliquot of feces was lyophilized for each sample and dry matter 
weights were obtained. DNA was extracted from the lyophilized fecal samples with a 
commercially available kit (PowerSoil® DNA Isolation Kit, MOBIO Laboratories, Inc., 
Carlsbad, CA, USA) and DNA concentration measured (Spectrophotometer, Nanodrop 
1000, Thermo Scientific, Rockford, IL, USA). DNA was normalized for concentration 
on a 96-well plate using a pipetting robot (epMotion 5075 Vacuum TMX, Eppendorf 
AG, Hamburg, Germany). Separate real-time quantitative polymerase chain reaction 
(qPCR) assays were used to amplify and quantify DNA from eleven different bacterial 
groups (Universal, Faecalibacterium spp., Turicibacter spp., Streptococcus spp., 
Escherichia coli, Blautia spp., Fusobacterium spp., Clostridium hiranonis, Lactobacillus 
spp., Bifidobacterium spp., and Enterococcus spp.) using protocols and primers 
described in Table 6. SYBR-based reaction mixtures (total 10 µl) contained 5 µl 
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SsoFast™ EvaGreen® Supermix (Bio-Rad Laboratories, CA, USA), 2.2 µl water, 0.4 µl 
of each primer (final concentration: 400 nM), and 2 µl of normalized DNA (final 
concentration: 5 ng/µl). A melt curve analysis was performed after the amplification 
cycles as follows: increments of 0.5°C from 65°C to 95°C for 5 seconds each. Samples 
were analyzed in duplicate fashion, and a commercially available qPCR thermal cycler 
(CFX96TM, Bio-Rad Laboratories, CA, USA) was used for all qPCR assays. 
The abundance of bacterial DNA for each bacterial group was compared between 
diseased groups and healthy controls. Additionally, microbiota data was expressed as a 
previously described Dysbiosis Index (AlShawaqfew et al., 2016; Suchodolski, 2016), 
where a Dysbiosis Index below zero is indicative of a healthy microbiota. 
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Table 6. Primers and cycling conditions used in qPCRs.  
Target Primer sequences (5' - 3') 
Initial 
denaturing 
temp(°C), 
time 
# of 
cycles 
Denaturing 
temp(°C), 
time 
Annealing 
temp(°C), 
time 
Reference 
Universal F-CCTACGGGAGGCAGCAGT                  
R-ATTACCGCGGCTGCTGG 
98,                  
2 min 
35 98,              
5 sec 
59,             
5 sec 
Lubbs et al., 
2009 
Faecalibacterium 
spp. 
F-GAAGGCGGCCTACTGGGCAC             
R-GTGCAGGCGAGTTGCAGCCT  
98,              
2 min 
40 98,              
5 sec 
60,             
5 sec 
Garcia-Mazcorro 
et al., 2012 
Turicibacter spp. F-CAGACGGGGACAACGATTGGA         
R-TACGCATCGTCGCCTTGGTA 
98,              
2 min 
40 98,              
3 sec 
57,             
3 sec 
Suchodolski et 
al., 2012 
Streptococcus spp. F-TTATTTGAAAGGGGCAATTGCT          
R-GTGAACTTTCCACTCTCACAC 
95,              
2 min 
40 95,              
5 sec 
54,           
10 sec 
Furet et al., 2004 
Escherichia coli F-GTTAATACCTTTGCTCATTGA            
R-ACCAGGGTATCTAATCCTGTT 
98,              
2 min 
40 98,              
3 sec 
55,             
3 sec 
Malinen et al., 
2005 
Blautia spp. F-TCTGATGTGAAAGGCTGGGGCTTA    
R-GGCTTAGCCACCCGACACCTA 
98,              
2 min 
40 98,              
4 sec 
56,             
4 sec 
Suchodolski et 
al., 2012 
Fusobacterium spp. F-KGGGCTCAACMCMGTATTGCGT       
R-TCGCGTTAGCTTGGGCGCTG 
98,              
2 min 
40 98,              
4 sec 
50.5,          
4 sec 
Suchodolski et 
al., 2012 
Clostridium 
hiranonis 
F-AGTAAGCTCCTGATACTGTCT            
R-AGGGAAAGAGGAGATTAGTCC 
95,              
3 min 
40 95,            
30 sec 
59,             
5 sec 
Kitahara et al., 
2001 
Lactobacillus spp. F-AGCAGTAGGGAATCTTCCA*               
R-CACCGCTACACATGGAG** 
95,              
2 min 
40 95,              
5 sec 
58,           
10 sec 
Malinen et al., 
2005 
Bifidobacterium spp. F-TCGCGTCYGGTGTGAAAG                   
R-CCACATCCAGCRTCCAC 
98,              
2 min 
40 98,              
3 sec 
60,             
3 sec 
Rinttila et al., 
2004 
Enterococcus spp. F-CCCTTATTGTTAGTTGCCATCATT      
R-ACTCGTTGTACTTCCCATTGT 
98,              
3 min 
40 98,              
3 sec 
61,             
3 sec 
Malinen et al., 
2005 
*Originally described by Walter et al., 2001. **Originally described by Heilig et al., 2002 
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2.6 Statistical Analysis of Results 
 All statistical analysis was performed with GraphPad Prism 5 (GraphPad 
Software, La Jolla, California, USA) or JMP® Pro 12.2.0 (64-bit, SAS Institute Inc.). 
Shapiro-Wilk test for normality was used to determine nonparametric distribution of 
data. Kruskal-Wallis tests were used to evaluate differences in variables between 
diseased and healthy groups. For post hoc analysis, we chose to use Steel-Dwass test for 
multiple comparisons with control (healthy group) test to independently compare ranks 
of each group to healthy dogs. Spearman’s rank correlation analysis was performed on 
the subset of dogs with EPI for which duration of enzyme therapy was known (n=12). 
Fisher’s exact test was used to compare proportions of dogs with a Dysbiosis index 
above zero and below zero. 
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3. RESULTS 
 
3.1 Analytical Validation of Assay for Measurement of Fecal Lactate 
 The lower limit of detection for D- and L-lactate concentrations were 0.0006 and 
0.0002 g/L, respectively. The lower limit of quantification for D- and L-lactate 
concentrations were 0.0021 and 0.0008 g/L, respectively. Observed-to-expected ratios 
for dilutional parallelism ranged from 92% to 111% for D-lactate, 89% to 109% for L-
lactate, and 88% to 104% for total lactate (Table 7). Recovery for spiking sample 
extracts ranged from 96% to 103% for D-lactate, 96% to 119% for L-lactate, and 98% to 
113% for total lactate (Table 8). Average intra-assay coefficients of variation for D-, L-, 
and total lactate were 5%, 5%, and 4%, respectively (Table 9). Average inter-assay 
%CVs for D-, L-, and total lactate were 24%, 20%, and 19%, respectively (Table 10). 
Fecal lactate was stable in deproteinized fecal extracts for 24 hours of storage at 4°C 
(average %CV: 9, 4, 4, for D-, L-, and total lactate, respectively; Table 11) and 28 days 
of storage at -80°C (average %CV: 4, 4, 3, for D-, L-, and total lactate, respectively; 
Table 12). Canine fecal lactate reference interval was 0.7-1.4 mM, 0.3-6.0 mM, and 1.0-
7.0 mM for D-, L-, and total lactate, respectively.  
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Table 7. Dilutional parallelism of seven fecal samples. Observed-to-expected ratios are 
in bold and the minimum, maximum, mean, and standard deviation of those observed-to-
expected ratios are provided in the box at the end of the table. 
  D-lactate L-lactate total lactate 
Sample 
1 O E OE% O E OE% O E OE% 
S1 HIGH     HIGH           
S1 1:2 HIGH N/A N/A HIGH N/A N/A N/A N/A N/A 
S1 1:4 0.047 N/A N/A HIGH N/A N/A N/A N/A N/A 
S1 1:10 0.021 0.019 112 HIGH N/A N/A N/A N/A N/A 
S1 1:20 0.011 0.009 112 0.033 N/A N/A 0.043 N/A N/A 
S1 1:40 0.005 0.005 102 0.014 0.016 87 0.019 0.022 88 
S1 1:80 LOW 0.002 N/A 0.007 0.008 91 N/A N/A N/A 
Sample 
2           
S2 HIGH     HIGH           
S2 1:2 HIGH N/A N/A HIGH N/A N/A N/A N/A N/A 
S2 1:4 0.030 N/A N/A HIGH N/A N/A N/A N/A N/A 
S2 1:10 0.013 0.012 106 HIGH N/A N/A N/A N/A N/A 
S2 1:20 0.005 0.006 89 0.028 N/A N/A 0.033 N/A N/A 
S2 1:40 0.003 0.003 92 0.014 0.014 104 0.017 0.017 104 
S2 1:80 LOW 0.002 N/A 0.007 0.007 100 N/A N/A N/A 
Sample 
3                   
S3 HIGH     HIGH           
S3 1:2 0.033 N/A N/A HIGH N/A N/A N/A N/A N/A 
S3 1:4 0.017 0.016 103 HIGH N/A N/A N/A N/A N/A 
S3 1:10 0.007 0.007 107 0.032 N/A N/A 0.039 N/A N/A 
S3 1:20 0.003 0.003 93 0.017 0.016 105 0.020 0.020 102 
S3 1:40 LOW 0.002 N/A 0.009 0.008 109 N/A N/A N/A 
S3 1:80 LOW 0.001 N/A 0.005 0.004 112 N/A N/A N/A 
Sample 
4                   
S4 HIGH     HIGH           
S4 1:2 0.048 N/A N/A HIGH N/A N/A N/A N/A N/A 
S4 1:4 0.028 0.024 117 HIGH N/A N/A N/A N/A N/A 
S4 1:10 0.011 0.010 117 0.028 N/A N/A 0.039 N/A N/A 
S4 1:20 0.005 0.005 99 0.013 0.014 96 0.018 0.019 93 
S4 1:40 LOW 0.002 N/A 0.007 0.007 102 N/A N/A N/A 
S4 1:80 LOW 0.001 N/A 0.003 0.003 101 N/A N/A N/A 
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Table 7 Continued 
  D-lactate L-lactate total lactate 
Sample 
5 O E OE% O E OE% O E OE% 
S5 0.044     HIGH           
S5 1:2 0.020 0.022 89 0.044 N/A N/A 0.064 N/A N/A 
S5 1:4 0.011 0.011 96 0.020 0.022 91 0.031 0.032 96 
S5 1:10 LOW 0.004 N/A 0.008 0.009 89 N/A N/A N/A 
S5 1:20 LOW 0.002 N/A 0.004 0.004 96 N/A N/A N/A 
S5 1:40 LOW 0.001 N/A LOW 0.002 N/A N/A N/A N/A 
S5 1:80 LOW 0.001 N/A LOW 0.001 N/A N/A N/A N/A 
Sample 
6                   
S6 0.007     0.027     0.034     
S6 1:2 0.003 0.004 93 0.014 0.013 102 0.017 0.017 101 
S6 1:4 LOW 0.002 N/A 0.007 0.007 111 N/A N/A N/A 
S6 1:10 LOW 0.001 N/A 0.003 0.003 109 N/A N/A N/A 
S6 1:20 LOW 0.000 N/A LOW 0.001 N/A N/A N/A N/A 
S6 1:40 LOW 0.000 N/A LOW 0.001 N/A N/A N/A N/A 
S6 1:80 LOW 0.000 N/A LOW 0.000 N/A N/A N/A N/A 
Sample 
7                   
S7 0.011     0.020     0.031     
S7 1:2 0.005 0.005 92 0.010 0.010 101 0.015 0.015 98 
S7 1:4 LOW 0.003 N/A 0.005 0.005 100 N/A N/A N/A 
S7 1:10 LOW 0.001 N/A LOW 0.002 N/A N/A N/A N/A 
S7 1:20 LOW 0.001 N/A LOW 0.001 N/A N/A N/A N/A 
S7 1:40 LOW 0.000 N/A LOW 0.000 N/A N/A N/A N/A 
S7 1:80 LOW 0.000 N/A LOW 0.000 N/A N/A N/A N/A 
  D-lactate L-lactate total lactate 
min 92 89 88 
max 111 109 104 
mean 99 100 97 
SD 7 7 5 
O = observed lactate concentration (g/L), E = expected lactate concentration (g/L), 
OE% = observed-to-expected ratio. 
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Table 8. Spiking recovery of four canine fecal samples. Observed-to-expected ratios are 
in bold and the minimum, maximum, mean, and standard deviation of those observed-to-
expected ratios are provided in the box at the end of the table. 
  D-lactate (mM) L-lactate (mM) total lactate (mM) 
Sample A 102 237 339 
Sample B 27 66 92 
Sample C 13 27 40 
Sample C 4 6 10 
            
  D-lactate L-lactate total lactate 
  O E OE% O E OE% O E OE% 
A+B 62 64 96 155 151 102 216 215 100 
A+C 58 58 101 127 132 96 185 189 98 
A+D 53 53 100 121 122 100 174 174 100 
            
B+A 62 64 96 155 151 102 216 215 100 
B+C 20 20 100 55 46 119 75 66 113 
B+D 15 15 98 40 36 113 55 51 108 
            
C+A 58 58 101 127 132 96 185 189 98 
C+B 20 20 100 55 46 119 75 66 113 
C+D 9 9 103 17 16 100 25 25 101 
            
D+A 53 53 100 121 122 100 174 174 100 
D+B 15 15 98 40 36 113 55 51 108 
D+C 9 9 103 17 16 100 25 25 101 
  D-lactate L-lactate total lactate 
min 96 96 98 
max 103 119 113 
mean 100 105 103 
SD 2 8 5 
O = observed lactate concentration (mM), E = expected lactate concentration (mM), OE% = 
observed-to-expected ratio, SD = standard deviation. 
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Table 9. Intra-assay variability of four canine fecal samples. Coefficients of variation 
are in bold and the minimum, maximum, mean, and standard deviation of these 
coefficients of variation are provided in the box at the end of the table. 
sample 1 2 3 4 
number of repeats 8 8 8 8 
  D-lactate 
mean (mM) 109 22 14 6 
standard deviation (mM) 6 1 1 0 
% CV 6 4 7 4 
  L-lactate 
mean (mM) 217 123 25 10 
standard deviation (mM) 16 7 1 0 
% CV 7 6 4 3 
  total lactate 
mean (mM) 327 145 39 16 
standard deviation (mM) 19 7 1 0 
% CV 6 5 3 3 
          
  D-lactate L-lactate total lactate 
min 4 3 3 
max 7 7 6 
mean 5 5 4 
SD 1 2 1 
%CV = coefficient of variation, SD = standard deviation. 
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Table 10. Inter-assay variability of seven canine fecal samples. Coefficients of variation 
are in bold and the minimum, maximum, mean, and standard deviation of these 
coefficients of variation are provided in the box at the end of the table. 
sample 1 2 3 4 5 6 7 
number of repeats 8 7* 8 8 8 8 8 
  D-lactate 
mean (mM) 75 106 20 29 15 3 4 
standard deviation (mM) 4 6 7 8 1 2 1 
% CV 6 5 32 29 5 56 31 
  L-lactate 
mean (mM) 233 224 143 76 30 7 7 
standard deviation (mM) 12 21 19 15 3 4 2 
% CV 5 10 13 20 11 55 28 
  total lactate 
mean (mM) 309 331 163 105 45 10 12 
standard deviation (mM) 16 24 18 23 4 5 3 
% CV 5 7 11 22 8 54 28 
                
  D-lactate L-lactate total lactate 
min 5 5 5 
max 56 55 54 
mean 23 20 19 
SD 18 16 16 
*one repeat was thrown out due to pipetting error 
%CV = coefficient of variation, SD = standard deviation. 
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Table 11. Stability of deproteinized fecal extracts for seven canine fecal samples at 4°C 
for 24 hours. Coefficients of variation are in bold and the mean of these coefficients of 
variation for D-, L-, and total lactate are provided. 
D-lactate           
sample 
inter-assay 
mean 
(mM) 
initial 
(mM) 
24h 
fridge 
(mM) 
% 
change %CV 
1 75 81 81 -2 0 
2 106 117 100 5 8 
3 20 10 15 0 22 
4 29 12 18 6 19 
5 15 16 14 6 9 
6 3 3 3 -1 1 
7 4 3 3 7 0 
     Mean %CV = 9 
L-lactate           
1 233 252 240 1 2 
2 224 242 239 -1 1 
3 143 160 167 -5 2 
4 76 46 43 14 3 
5 30 34 29 4 8 
6 7 8 9 -10 7 
7 7 7 6 9 7 
     Mean %CV = 4 
total lactate           
1 309 333 321 0 2 
2 331 360 339 1 3 
3 163 169 182 -5 3 
4 105 58 61 12 3 
5 45 50 43 5 8 
6 10 11 12 -8 5 
7 12 10 9 8 5 
        Mean %CV = 4 
%CV = coefficient of variation. 
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Table 12. Stability of deproteinized fecal extracts for seven canine fecal samples at         
-80°C for 4 weeks. Coefficients of variation are in bold and the mean of these 
coefficients of variation for D-, L-, and total lactate are provided. 
D-lactate           
sample 
inter-assay 
mean 
(mM) 
initial 
(mM) 
4wk 
freezer 
(mM) 
% 
change %CV 
1 75 71 72 1 1 
2 106 102 114 -5 5 
3 20 16 14 12 8 
4 29 24 25 2 3 
5 15 15 18 -10 9 
6 3 4 4 -8 2 
7 4 3 2 13 1 
     Mean %CV = 4 
L-lactate           
1 233 219 182 10 9 
2 224 185 191 3 2 
3 143 120 122 4 1 
4 76 64 66 3 2 
5 30 23 21 10 4 
6 7 10 9 -1 7 
7 7 5 4 13 2 
     Mean %CV = 4 
total lactate           
1 309 290 253 8 7 
2 331 287 305 1 3 
3 163 136 136 5 0 
4 105 87 91 3 2 
5 45 38 39 3 1 
6 10 14 13 -3 5 
7 12 7 7 13 2 
        Mean %CV = 3 
%CV = coefficient of variation. 
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3.2 Quantification of Lactate and Bacterial Groups in Canine Feces 
 Metadata was available for a portion of dogs included in the study and is 
presented in Table 13. Graphical representations of results are presented in Figures 2 
through 5. 
 
3.2.1 Dogs with AHD v Healthy Control Dogs 
D-, L-, and total fecal lactate concentrations were significantly increased in dogs 
with AHD compared to healthy control dogs (Table 14). Turicibacter, Blautia, C. 
hiranonis, and Enterococcus were significantly decreased in dogs with AHD compared 
to healthy control dogs (Table 14). 
 
3.2.2 Dogs with CE v Healthy Control Dogs 
 D-lactate concentrations in feces were significantly increased in dogs with CE 
compared to healthy control dogs (Table 14). Faecalibacterium, Blautia, and C. 
hiranonis were significantly decreased in dogs with CE compared to healthy control 
dogs (Table 14).  
 
3.2.3 Dogs with EPI v Healthy Control Dogs 
 Dogs with untreated and treated EPI had significantly increased D-, L-, and total 
fecal lactate concentrations (Table 14). Dogs with untreated and treated EPI also had 
significantly less abundance of Blautia and C. hiranonis when compared to healthy 
control dogs (Table 14). Dogs treated for EPI uniquely had increased abundance of 
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Lactobacillus and Bifidobacterium compared to healthy control dogs (Table 14). Both 
untreated and treated dogs with EPI had an increased Dysbiosis Index (Table 14). A 
subset of dogs treated for EPI (n=12), had received pancreatic enzyme replacement 
therapy for 0.08-9.50 years (median 4.45 years), and duration was negatively correlated 
with Turicibacter abundance (Spearman’s ρ= -0.634; p=0.0268). 
 
Table 13. Metadata for dogs included in the study, if available. 
  Healthy AHD CE 
Untreated 
EPI Treated EPI 
Age (years; 
median, range) 
6.5, 1-12 N/A 6, 3-11 2, 1.1-4 3.75 1-14 
Gender 
(female/male) 
10/8 N/A 2/4 2/3 21/7 
Breed (top 3, 
n) 
GSD (7), 
Miniature 
Schnauzer (3), 
Mixed breed 
(4) 
N/A Mixed breed 
(3), Other 
(11) 
GSD (3), 
Chihuahua (1), 
Pembroke 
Corgi (1) 
GSD (17), 
Mixed breed 
(2), Other (11) 
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Table 14. D-, L-, and total fecal lactate concentrations (median [min-max] mM), abundance of bacterial groups (median [min-
max] LogSQ) and Dysbiosis Index (median [min-max]) in disease dogs compared to healthy control dogs with Steel-Dwass 
test. If no p-value is listed, p ≥ 0.05. 
  Healthy AHD CE Untreated EPI Treated EPI 
D-lactate 
0.8 [0.7-1.3] 0.8 [0.5-47.1]; 
p=0.0428 
0.9 [0.7-22.5]; 
p=0.0416 
31.2 [13.1-57.3]; 
p=0.0033 
4.1 [0.7-53.3]; 
p=0.0002 
L-lactate 
0.6 [0.3-5.7] 5.4 [0.3-78.1]; 
p=0.0038 
1.4 [0.3-52.6] 68.5 [61.6-124.2]; 
p=0.0035 
9.3 [0.3-184.7]; 
p=0.0005 
Total lactate 
1.3 [1.1-6.6] 6.5 [1.1 -125.2]; 
p=0.0028 
2.2 [1.1-75.0] 103.1 [81.5-
181.4]; p=0.0035 
13.9 [1.0-233.6]; 
p=0.0006 
Universal 
11.60 [9.20-
12.08] 
11.56 [10.67-
12.14] 
11.60 [11.19-
12.05] 
11.67 [9.20-11.91] 11.81 [9.20-12.46] 
Faecalibacterium 
6.80 [4.12-7.71] 5.77 [4.28-7.62] 4.64 [2.82-7.80]; 
p=0.0256 
4.88 [3.82-7.25] 6.03 [4.05-7.76] 
Turicibacter 
6.27 [4.37-8.83] 4.40 [3.20-6.88]; 
p=0.0004 
5.20 [2.58-7.23] 4.73 [2.67-7.79] 7.50 [4.09-8.39] 
Streptococcus 
5.48 [3.80-8.43] 4.58 [3.25-7.71] 4.87 [3.80-8.75] 4.77 [3.80-9.04] 7.96 [3.80-9.49] 
Escherichia coli 
6.63 [4.27-10.61] 6.53 [3.72-8.72] 6.78 [3.32-8.85] 10.44 [3.32-11.36] 8.32 [4.89-11.94] 
Blautia 
10.72 [8.41-
11.15] 
7.80 [6.31-9.58]; 
p<0.0001 
9.70 [8.22-10.58]; 
p=0.0084 
8.79 [6.74-9.94]; 
p=0.0135 
9.15 [6.74-10.99]; 
p=0.0020 
Fusobacterium 
9.25 [7.23-10.14] 9.43 [7.23-10.41] 8.50 [6.68-10.48] 7.23 [7.23-9.87] 8.38 [7.23-10.54] 
Clostridium 
hiranonis 
6.16 [0.90-6.70] 4.89 [0.90-6.53]; 
p=0.0097 
5.26 [0.90-6.02]; 
p=0.0095 
0.90 [0.90-0.90]; 
p=0.0060 
5.35 [0.90-6.68]; 
p=0.0071 
Dysbiosis Index 
-3.8 [-7.6 to 3.3] -2.2 [-7.2 to 3.3] 0.1 [-7.2 to 7.4] 4.7 [-0.7 to 8.4]; 
p=0.0120 
-0.1 [-7.3 to 8.2]; 
p=0.0064 
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Table 14 Continued 
 Healthy AHD CE Untreated EPI Treated EPI 
Lactobacillus 
3.68 [3.68-8.43] 4.72 [3.68-7.69] 4.68 [3.68-6.51] 5.29 [3.68-8.65] 6.71 [3.82-8.66]; 
p=0.0001 
Bifidobacterium 
3.93 [3.20-7.30] 3.94 [3.20-6.06] 3.86 [3.20-6.54] 6.97 [3.20-8.12] 6.84 [3.20-8.64]; 
p<0.0001 
Enterococcus 
4.30 [1.68-6.78] 3.69 [1.66-5.23]; 
p=0.0070 
5.46 [1.72-7.22] 5.54 [1.68-8.11] 5.14 [2.79-7.13] 
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Figure 2. Lactate concentrations (mM) in the feces of healthy and diseased dogs. The groups on the x-axis are defined as 
follows: H = healthy dogs, AHD = dogs with acute hemorrhagic diarrhea, CE = dogs with chronic enteropathy, U-EPI = dogs 
with exocrine pancreatic insufficiency not receiving enzyme replacement therapy, T-EPI = dogs with exocrine pancreatic 
insufficiency receiving enzyme replacement therapy. 
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Figure 3. Bacterial abundances of those bacterial groups used to calculate Dysbiosis Index in the feces of healthy and diseased 
dogs. 
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Figure 4. Dysbiosis Index for healthy and diseased dogs. 
Dysbiosis Index
IN
D
E
X
H
A
H
D
C
E
U
-E
PI
T-
E
PI
-10
-5
0
5
10
 46 
 
 
Figure 5. Abundance of specific lactate-producing bacterial groups in healthy and diseased dogs.
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4. DISCUSSION 
 
4.1 Analytical Validation of an Assay for Measurement of Fecal Lactate 
An enzymatic assay for the measurement of D-, L-, and total lactate in canine 
feces was successfully established for use in a 96-well plate format. Generally 
acceptable observed-to-expected ratios for dilutional parallelism and spiking recovery 
fall between 80% and 120%. Observed-to-expected ratios for dilutional parallelism 
ranged from 92% to 111% for D-lactate, 89% to 109% for L-lactate, and 88% to 104% 
for total lactate (Table 7), which suggests the assay is linear. Observed-to-expected 
ratios for spiking recovery ranged from 96% to 103% for D-lactate, 96% to 119% for L-
lactate, and 98%-113% for total lactate (Table 8), which suggests the assay is accurate. 
Generally acceptable coefficients of variation for intra- and inter-assay variability differ 
for different types of assays, but are best under 15%. Average intra-assay coefficients of 
variation for D-, L-, and total lactate were 5%, 5%, and 4%, respectively (Table 9), 
which suggests the assay is precise. Average inter-assay coefficients of variation for D-, 
L-, and total lactate were 24%, 20%, and 19%, respectively (Table 10). Some of this 
inter-assay variation can be explained by the methodology used for validation. Separate 
fecal aliquots were made for each sample to be analyzed in inter-assay variation. 
Therefore, potential variation could be also due to some differences in the distribution of 
lactate in feces. More studies need to be performed to determine the variation of lactate 
within stool samples. However, our analysis suggests that the assay is reproducible to 
differentiate lactate concentration across the disease populations. 
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Lactate was stable in deproteinized fecal extracts for 24 hours of storage at 4°C 
(average %CV: 9, 4, 4, for D-, L-, and total lactate, respectively; Table 11) and 28 days 
of storage at -80°C (average %CV: 4, 4, 3, for D-, L-, and total lactate, respectively; 
Table 12).  
The reference interval for canine fecal lactate (n=34) was 0.7-1.4 mM, 0.3-6.0 
mM, and 1.0-7.0 mM for D-, L-, and total lactate, respectively. The assay has a working 
range of 0.007 to 0.581 mM for D-lactate, and 0.003 to 0.581 mM for L-lactate, as 
determined by the lower limit of detection and highest standard concentration. After 
dilution that occurred during the deproteinization procedure, all reference samples fell 
below or within this range.  
In summary, the assay for measurement of D-, L-, and total lactate in canine fecal 
samples was linear, accurate, precise, and reproducible.  
 
4.2 Quantification of Lactate and Bacterial Groups in Canine Feces 
 This study quantified D-, L-, and total lactate as well as major bacterial groups in 
feces of healthy dogs and dogs with various gastrointestinal diseases. Significant 
differences were observed in concentrations of fecal lactate between diseased and 
healthy dogs (Table 14, Figure 2). Dogs with exocrine pancreatic insufficiency had the 
highest fecal lactate concentrations followed by dogs with acute hemorrhagic diarrhea. 
Dogs with chronic enteropathy had a significant increase in D-lactate concentrations, 
however, L-lactate and total lactate did not reach the level of significance. Blautia and 
Clostridium hiranonis were significantly decreased in all diseased groups compared to 
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healthy dogs (Table 14, Figure 3). Dogs with chronic enteropathy also had decreased 
Faecalibacterium spp. and dogs with acute hemorrhagic diarrhea had decreased 
Turicibacter (Table 14, Figure 3). The Dysbiosis Index tended to increase in dogs with 
AHD (p=0.3256) and CE (p=0.0745), however, it did not reach the level of significance 
(Figure 4). Although the proportion of dogs with a Dysbiosis Index above zero was also 
higher in dogs with AHD (35%) or CE (53%) compared to healthy dogs (17%), these 
comparisons did not reach the level of significance (p=0.2778 and p=0.0613, 
respectively). Three additional lactate-producing bacterial groups were quantified in the 
feces; Lactobacillus spp., Bifidobacterium spp., and Enterococcus spp. The taxa 
Enterococcus spp. were uniquely decreased in dogs with acute hemorrhagic diarrhea, 
and Lactobacillus spp. and Bifidobacterium spp. were uniquely decreased in dogs 
receiving enzyme replacement therapy for EPI. Both treated and untreated dogs with EPI 
had a dysbiosis as indicated by the significantly increased DI (Table 14, Figure 4).  
 Statistical differences were not found for abundances of lactate-producing 
bacteria in dogs not receiving enzyme replacement therapy for EPI, most likely due to 
the small number of animals analyzed in this group (n=5). For ethical reasons, it is 
difficult to obtain fecal samples from dogs diagnosed with EPI that have not received 
treatment. The diagnostic test for EPI is a serum trypsin-like immunoreactivity of less 
than 2.5 µg/L. Once diagnosed, treatment should not be delayed for the sole purpose of 
collecting feces for analysis.  
 It was previously mentioned that nutritional studies often aim to increase lactate 
concentrations or lactic acid bacteria abundance within the GI tract. However, these 
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dietary interventions produce only minor changes relative the changes observed in this 
study. Fructooligosaccharide supplementation in dogs increased mean counts of 
Bifidobacterium and Lactobacillus by 0.58 and 0.66 cfu log10/g DM, respectively, and 
increased mean fecal lactate by 0.053 mmol (Swanson et al., 2002a). Similarly in 
humans, fructooligosaccharide supplementation increased fecal Bifidobacterium and 
Lactobacillus by less than 0.5 log10/g wet feces and increased fecal lactate by 0.019 
mmol/g dry feces (Ten Bruggencate et al., 2006). In contrast, dogs with EPI (treated) in 
this study showed increases in Bifidobacterium and Lactobacillus of 2.91 and 3.03 
LogSQ, respectively, and increased fecal lactate concentrations by 12.6 mmol/L. Minor 
increases in lactate or lactate-producing bacteria in the GI tract may have some 
beneficial effects, but the GI disease processes shown here are likely to have a much 
more profound impact on any changes observed in the microbiota or their metabolites. 
Moreover, other factors, such as pH, may influence the metabolic activities of the 
microbiota without actually changing the abundance of any bacterial groups (Edwards et 
al., 1985).  
 The results of this study are in agreement with previous studies that examine the 
fecal microbiota composition of dogs with GI disease. In one study using 454-
pyrosequencing and qPCR analysis, dogs with acute hemorrhagic diarrhea had decreases 
in Blautia, Faecalibacterium, and Turicibacter spp. when compared to healthy dogs 
(Suchodolski et al., 2012). Decreased proportions of Bacteroidetes, Faecalibacterium, 
and an unclassified genus within Ruminococcaceae were also observed in dogs with 
hemorrhagic and non-hemorrhagic acute diarrhea, and no differences were identified in 
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Bifidobacterium, Lactobacillus, or E. coli (Guard et al., 2015). Similarly, this study 
observed significant decreases in Blautia and Turicibacter abundance and no difference 
in Bifidobacterium, Lactobacillus, or E. coli when dogs with acute hemorrhagic diarrhea 
were compared to healthy dogs.  
Dysbiosis is typically associated with alterations in the predominant bacterial 
groups, such as the eight groups tested here, and has recently been linked to alterations 
in bacterial metabolites, such as SCFAs, secondary bile acids, and other 
immunomodulatory metabolites (Suchodolski, 2016). Accordingly, in dogs with acute 
diarrhea, decreased abundances of Faecalibacterium spp. were correlated with increases 
in butyrate and decreases in propionate concentrations in the feces (Guard et al., 2015). 
Furthermore, alterations of the microbiota in dogs with inflammatory bowel disease 
(IBD), a type of chronic enteropathy, were associated with changes in the functional 
gene content and serum metabolites (Minamoto et al., 2015). Microbiota changes shown 
by qPCR abundances in feces of dogs with IBD included significantly decreased Blautia, 
Faecalibacterium, and Turicibacter spp. (Minamoto et al., 2015), which agrees with our 
results. However, in the group of dogs with chronic enteropathy presented here, there 
was no significant decrease in abundance of Turicibacter. This could be attributed in 
part to individual variation in the microbiota composition, as described elsewhere (Blake 
and Suchodolski, 2016).  
A recent study identified differences in the microbiota and functional gene 
content of dogs with EPI using next generation sequencing and PICRUSt (Isaiah et al., 
2017). Again, in agreement with our findings, decreases in Faecalibacterium and 
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Blautia and increases in Lactobacillus and Bifidobacterium were found in dogs with EPI 
compared to healthy dogs (Isaiah et al., 2017). Additionally, Coprococcus, 
Ruminococcus, Eubacterium, Bacteroides, Slackia, and Fusobacterium were decreased 
and Enterococcus were increased in dogs with EPI (Isaiah et al., 2017). Dogs with EPI 
often have a concurrent overgrowth of bacteria in their small intestine (Westermarck et 
al., 1993), and it is unclear whether bacterial quantification in the feces is directly 
representative of bacteria present in the small intestine. Recently, Honneffer et al. (2017) 
reported that the microbiota and microbial metabolites vary along the gastrointestinal 
tract in healthy dogs. However, in dogs with IBD, similar changes in the microbiota 
were observed in the small intestine and fecal samples, suggesting that dysbiosis 
originating in the small intestine can still be detected in the feces (Suchodolski, 2016).  
Antibiotics are often administered to dogs with EPI to combat the overgrowth of 
bacteria in the small intestine, despite evidence of pancreatic enzyme replacement 
therapy modulating bacteria levels alone (German, 2012). Alterations in the microbiota 
have been described in association with antibiotic usage (Minamoto et al., 2015), and a 
recent study has suggested that dysbiosis can be induced by antibiotic administration in 
healthy dogs (Suchodolski et al., 2016). For these reasons, we included only dogs that 
had not received antibiotics for at least three weeks prior to feces collection.  
 
4.3 Strengths and Limitations 
 In addition to the small sample sizes obtained for some of the diseased groups, 
this study was limited by the lack of background information available for dogs included 
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in the study, especially lack of information on antibiotic usage. Although no dogs were 
administered antibiotics in the three weeks prior to fecal collection, full prior history of 
antibiotic usage was not available for some dogs. Many of the samples used were left 
over from other studies and this information could not be obtained retrospectively from 
owners. However, some dogs included in our study had not received antibiotics for at 
least 6 months prior to collection and differences in these dogs were similar to the rest of 
their prospective disease groups. Furthermore, none of the dogs with AHD had a known 
history of antibiotic usage. Recognizing that type and duration of antibiotic 
administration may result in different changes to the microbiota, this information is 
imperative to future studies. Studies of antibiotic administration to healthy humans has 
suggested that severe shifts in the microbial populations are induced, and certain 
bacterial groups may not return to normal for up to 12 months (Dethlefsen et al., 2008; 
Rashid et al., 2015). Ideally, future studies should be performed on animals with no 
history of antibiotic usage. However, this may be unrealistic because antibiotics are 
often used as a first or second line of defense when companion animals are experiencing 
diarrhea or vomiting. In addition, there is anecdotal evidence that animals improve 
clinically with antibiotics.  
 The validated enzymatic assay for the quantification of lactate in canine feces has 
some strengths and limitations of its own. The 96-well plate format allows up to 37 
samples to be analyzed at once and is cost efficient compared to other methods of 
analysis. The narrow working range of the assay may be considered a limitation; 
however, samples above the working range can be diluted easily. The healthy reference 
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interval for lactate does not exceed the upper limit of the working range. Therefore, we 
can deduce that samples with lactate concentrations above the working range of the 
assay are abnormal.  
 
4.4 Applications, Implications, and Outlook 
 The assay for measurement of lactate in canine feces has made available the 
opportunity to obtain concentrations of fecal lactate in future studies on gastrointestinal 
diseases in companion animals. We have directly measured lactate concentrations as 
well as bacterial abundances of groups thought to produce lactate in the feces of dogs. 
These findings support the theory of lactate accumulation described by Ewaschuk et al. 
(2005), where lactate accumulates in association with increased lactic acid bacteria such 
as Lactobacillus spp. However, this theory might not explain lactate accumulation in all 
cases, as shown by the accumulation of lactate in feces of dogs with acute hemorrhagic 
diarrhea and chronic enteropathy without concurrent increases in lactate-producing 
bacterial groups. Future work could examine lactate consuming bacterial groups or look 
at the microbial metabolites in a broader sense to understand the metabolic changes 
occurring in diseased states. In perspective of the current knowledge, our findings do not 
support the theory that D-lactic acidosis is caused solely by overproduction of lactate by 
bacterial groups in the gastrointestinal tract, as an increase in luminal D-lactate appears 
to occur frequently in GI disease. Overproduction of lactate may be one component in 
the development of acidosis, but other components, such as abnormal intestinal barrier 
function, could also potentially be involved. There was no prevalence of obvious 
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neurologic signs in dogs included in this study despite all disease groups having a 
significantly increased concentration of D-lactate in the feces compared to healthy dogs 
based on owner questionnaires. Other mechanisms, such as increased absorption or 
impaired metabolism of D-lactate, should be examined in the development of lactic 
acidosis.  
 Our findings raise several new questions that could be addressed in future work. 
Fecal lactate may influence serum lactate concentrations on a subclinical level and could 
be clinically useful information in certain disease processes such as shock and sepsis. 
This study did not identify the origin of the lactate molecules present in the feces, and 
since lactate is also produced by host cells (albeit in small amounts), one question that 
needs to be answered is ‘where is the lactate coming from?’. It is possible that in certain 
disease processes where the intestinal epithelium undergoes oxidative stress (i.e. 
inflammation), epithelial cells will produce and excrete higher amounts of lactate into 
the intestinal lumen.  
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5. CONCLUSION 
 
An enzymatic assay for the measurement of D-, L-, and total lactate in canine 
feces was successfully established for use in a 96-well plate format. The assay was 
linear, accurate, precise, and reproducible. We then quantified D-, L-, and total lactate as 
well as major bacterial groups in feces of healthy dogs and dogs with various 
gastrointestinal diseases. Significant increases in fecal lactate concentrations were 
observed in dogs with acute hemorrhagic diarrhea, dogs with chronic enteropathy (D-
lactate only), and dogs with exocrine pancreatic insufficiency. Blautia and Clostridium 
hiranonis were significantly decreased in all diseased groups compared to healthy dogs. 
While alterations in other bacterial groups were present in the various diseases studied, 
dogs with exocrine pancreatic insufficiency had the most profound alterations as 
evidenced by their significantly increased Dysbiosis Index.  
In conclusion, further studies are necessary to determine the clinical utility of 
lactate quantification in canine feces. Though lactate by itself may not be a good 
indicator of dysbiosis, bacterial metabolites together with bacterial abundances are 
promising targets for further elucidating the role of the microbiota in health and disease.  
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